Cadrenal Therapeutics, Inc. is a biopharmaceutical company that specializes in clinical development. They are focused on creating Tecarfarin, an orphan drug that prevents systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. Headquartered in Ponte Vedra, Florida, the company was established in 2022.